Cargando…
Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications
The epithelial cell adhesion molecule (EpCAM) is a cell surface glycoprotein, which is widely expressed on normal and cancer cells. EpCAM is involved in cell adhesion, proliferation, survival, stemness, and tumorigenesis. Therefore, EpCAM is thought to be a promising target for cancer diagnosis and...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220218/ https://www.ncbi.nlm.nih.gov/pubmed/35735360 http://dx.doi.org/10.3390/antib11020041 |
_version_ | 1784732318931353600 |
---|---|
author | Li, Guanjie Suzuki, Hiroyuki Asano, Teizo Tanaka, Tomohiro Suzuki, Hiroyoshi Kaneko, Mika K. Kato, Yukinari |
author_facet | Li, Guanjie Suzuki, Hiroyuki Asano, Teizo Tanaka, Tomohiro Suzuki, Hiroyoshi Kaneko, Mika K. Kato, Yukinari |
author_sort | Li, Guanjie |
collection | PubMed |
description | The epithelial cell adhesion molecule (EpCAM) is a cell surface glycoprotein, which is widely expressed on normal and cancer cells. EpCAM is involved in cell adhesion, proliferation, survival, stemness, and tumorigenesis. Therefore, EpCAM is thought to be a promising target for cancer diagnosis and therapy. In this study, we established anti-EpCAM monoclonal antibodies (mAbs) using the Cell-Based Immunization and Screening (CBIS) method. We characterized them using flow cytometry, Western blotting, and immunohistochemistry. One of the established recombinant anti-EpCAM mAbs, recEpMab-37 (mouse IgG(1), kappa), reacted with EpCAM-overexpressed Chinese hamster ovary-K1 cells (CHO/EpCAM) or a colorectal carcinoma cell line (Caco-2). In contrast, recEpMab-37 did not react with EpCAM-knocked out Caco-2 cells. The K(D) of recEpMab-37 for CHO/EpCAM and Caco-2 was 2.0 × 10(−8) M and 3.2 × 10(−8) M, respectively. We observed that EpCAM amino acids between 144 to 164 are involved in recEpMab-37 binding. In Western blot analysis, recEpMab-37 detected the EpCAM of CHO/EpCAM and Caco-2 cells. Furthermore, recEpMab-37 could stain formalin-fixed paraffin-embedded colorectal carcinoma tissues by immunohistochemistry. Taken together, recEpMab-37, established by the CBIS method, is useful for detecting EpCAM in various applications. |
format | Online Article Text |
id | pubmed-9220218 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92202182022-06-24 Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications Li, Guanjie Suzuki, Hiroyuki Asano, Teizo Tanaka, Tomohiro Suzuki, Hiroyoshi Kaneko, Mika K. Kato, Yukinari Antibodies (Basel) Article The epithelial cell adhesion molecule (EpCAM) is a cell surface glycoprotein, which is widely expressed on normal and cancer cells. EpCAM is involved in cell adhesion, proliferation, survival, stemness, and tumorigenesis. Therefore, EpCAM is thought to be a promising target for cancer diagnosis and therapy. In this study, we established anti-EpCAM monoclonal antibodies (mAbs) using the Cell-Based Immunization and Screening (CBIS) method. We characterized them using flow cytometry, Western blotting, and immunohistochemistry. One of the established recombinant anti-EpCAM mAbs, recEpMab-37 (mouse IgG(1), kappa), reacted with EpCAM-overexpressed Chinese hamster ovary-K1 cells (CHO/EpCAM) or a colorectal carcinoma cell line (Caco-2). In contrast, recEpMab-37 did not react with EpCAM-knocked out Caco-2 cells. The K(D) of recEpMab-37 for CHO/EpCAM and Caco-2 was 2.0 × 10(−8) M and 3.2 × 10(−8) M, respectively. We observed that EpCAM amino acids between 144 to 164 are involved in recEpMab-37 binding. In Western blot analysis, recEpMab-37 detected the EpCAM of CHO/EpCAM and Caco-2 cells. Furthermore, recEpMab-37 could stain formalin-fixed paraffin-embedded colorectal carcinoma tissues by immunohistochemistry. Taken together, recEpMab-37, established by the CBIS method, is useful for detecting EpCAM in various applications. MDPI 2022-06-08 /pmc/articles/PMC9220218/ /pubmed/35735360 http://dx.doi.org/10.3390/antib11020041 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Li, Guanjie Suzuki, Hiroyuki Asano, Teizo Tanaka, Tomohiro Suzuki, Hiroyoshi Kaneko, Mika K. Kato, Yukinari Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications |
title | Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications |
title_full | Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications |
title_fullStr | Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications |
title_full_unstemmed | Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications |
title_short | Development of a Novel Anti-EpCAM Monoclonal Antibody for Various Applications |
title_sort | development of a novel anti-epcam monoclonal antibody for various applications |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220218/ https://www.ncbi.nlm.nih.gov/pubmed/35735360 http://dx.doi.org/10.3390/antib11020041 |
work_keys_str_mv | AT liguanjie developmentofanovelantiepcammonoclonalantibodyforvariousapplications AT suzukihiroyuki developmentofanovelantiepcammonoclonalantibodyforvariousapplications AT asanoteizo developmentofanovelantiepcammonoclonalantibodyforvariousapplications AT tanakatomohiro developmentofanovelantiepcammonoclonalantibodyforvariousapplications AT suzukihiroyoshi developmentofanovelantiepcammonoclonalantibodyforvariousapplications AT kanekomikak developmentofanovelantiepcammonoclonalantibodyforvariousapplications AT katoyukinari developmentofanovelantiepcammonoclonalantibodyforvariousapplications |